Vericel (NASDAQ:VCEL) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Vericel (NASDAQ:VCEL) in a report released on Wednesday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $19.00 price target on the biotechnology company’s stock.

Several other analysts have also commented on the company. BTIG Research set a $24.00 price objective on Vericel and gave the stock a buy rating in a report on Monday, August 12th. Zacks Investment Research raised Vericel from a hold rating to a buy rating and set a $17.00 price objective for the company in a report on Saturday, October 5th. ValuEngine lowered Vericel from a buy rating to a hold rating in a report on Wednesday, October 2nd. Finally, BidaskClub lowered Vericel from a hold rating to a sell rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $21.98.

Shares of VCEL opened at $14.45 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.50 and a quick ratio of 7.12. Vericel has a one year low of $10.51 and a one year high of $21.00. The firm has a market capitalization of $637.78 million, a P/E ratio of -103.21 and a beta of 2.66. The business has a fifty day moving average of $15.67 and a 200 day moving average of $17.12.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.42. Vericel had a negative return on equity of 0.99% and a negative net margin of 18.14%. The company had revenue of $26.15 million during the quarter, compared to analyst estimates of $24.13 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. Vericel’s revenue was up 37.6% compared to the same quarter last year. Analysts expect that Vericel will post 0.09 EPS for the current fiscal year.

In other Vericel news, CEO Dominick Colangelo sold 58,125 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $14.88, for a total transaction of $864,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Gerard J. Michel sold 17,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $16.62, for a total value of $282,540.00. The disclosure for this sale can be found here. Insiders sold 92,125 shares of company stock valued at $1,482,000 in the last ninety days. 4.50% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. River & Mercantile Asset Management LLP bought a new stake in Vericel during the second quarter valued at about $2,450,000. Chartwell Investment Partners LLC grew its holdings in Vericel by 124.6% during the second quarter. Chartwell Investment Partners LLC now owns 84,487 shares of the biotechnology company’s stock valued at $1,596,000 after purchasing an additional 46,874 shares during the period. Royal Bank of Canada grew its holdings in Vericel by 665.8% during the second quarter. Royal Bank of Canada now owns 1,547 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,345 shares during the period. United Services Automobile Association grew its holdings in Vericel by 9.3% during the second quarter. United Services Automobile Association now owns 275,243 shares of the biotechnology company’s stock valued at $5,199,000 after purchasing an additional 23,491 shares during the period. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in Vericel by 52.0% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 16,515 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 5,651 shares during the period. 88.74% of the stock is owned by institutional investors and hedge funds.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Read More: How to find the components of the quick ratio

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.